VERVVerve Therapeutics, Inc.

Nasdaq vervetx.com


$ 4.89 $ 0.12 (2.52 %)    

Friday, 28-Jun-2024 15:59:53 EDT
QQQ $ 479.98 $ -2.50 (-0.52 %)
DIA $ 391.11 $ -0.43 (-0.11 %)
SPY $ 544.70 $ -2.15 (-0.39 %)
TLT $ 91.77 $ -1.74 (-1.86 %)
GLD $ 215.03 $ 0.02 (0.01 %)
$ 4.88
$ 4.82
$ 0.00 x 0
$ 0.00 x 0
$ 4.59 - $ 4.93
$ 4.59 - $ 21.04
3,122,526
na
405.69M
$ 2.24
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 02-27-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-15-2023 03-31-2023 10-Q
6 03-02-2023 12-31-2022 10-K
7 11-07-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-10-2022 03-31-2022 10-Q
10 03-14-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cathie-woods-ark-invest-sells-coinbase-shares-as-bitcoin-drops-below-key-62k-level

On Monday, Cathie Wood-led Ark Invest made some significant trades, with Coinbase Global Inc. (NASDAQ:COIN) taking the spotligh...

 cathie-wood-led-ark-invest-sells-15m-worth-of-robinhood-shares-amid-muted-bitcoin-market--also-dumps-zoom-stock-worth-33m

Ark Invest, led by Cathie Wood, made significant trades on Wednesday involving Robinhood Markets Inc (NASDAQ:HOOD) and Zoom Vid...

 cathie-wood-lead-ark-invest-dumps-76m-worth-of-robinhood-shares-amid-gamestop-buzz-bitcoin-choppiness

On Monday, Cathie Wood-led Ark Invest made a significant move by reducing its holdings in Robinhood Markets Inc (NASDAQ:HOOD). ...

 cathie-woods-ark-innovation-etf-sees-sharp-decline-among-top-holdings--here-are-10-largest-losers-within-arkf

Cathie Wood's flagship ARK Innovation ETF has been navigating through significant losses, showcasing the challenges faced b...

 hc-wainwright--co-reiterates-buy-on-verve-therapeutics-maintains-15-price-target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Verve Therapeutics (NASDAQ:VERV) with a Buy and maintains $15 pri...

 top-3-health-care-stocks-which-could-rescue-your-portfolio-this-quarter

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

 cathie-woods-ark-invest-sheds-64m-worth-of-coinbase-shares-despite-positive-market-movements-analyst-upgrade

On Thursday, Cathie Wood-led Ark Invest made a significant move by selling shares of Coinbase Global Inc (NASDAQ:COIN), despite...

 stifel-maintains-buy-on-verve-therapeutics-lowers-price-target-to-40

Stifel analyst Dae Gon Ha maintains Verve Therapeutics (NASDAQ:VERV) with a Buy and lowers the price target from $56 to $40.

 nasdaq-down-over-1-vivopower-international-shares-spike-higher

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dipping over 1% on Tuesday. The Dow traded down ...

 why-stryve-foods-shares-are-trading-lower-by-around-25-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Stryve Foods, Inc. (NASDAQ: SNAX) fell sharply during Tuesday’s session following a fourth-quarter revenue miss.

 gene-therapy-side-effects-verve-therapeutics-halts-enrollment-of-lead-gene-therapy-trial-in-patients-with-bad-cholesterol

Verve Therapeutics' latest update on the Heart-1 Phase 1b trial of VERVE-101. Explore VERVE-102's development and regul...

 crude-oil-surges-over-1-us-factory-orders-increase-in-february

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% on Tuesday. The Dow traded dow...

 verve-therapeutics-announces-updates-on-pcsk9-program-company-to-pause-enrollment-in-heart-1-clinical-trial-following-asymptomatic-grade-3-transient-alt-elevation-and-thrombocytopenia-seen-in-sixth-participant-enrolled-in-045-mgkg-dose-cohort

VERVE-101 is being evaluated in the Heart-1 Phase 1b clinical trial with trial endpoints of safety and tolerability as well as ...

 rbc-capital-reiterates-outperform-on-verve-therapeutics-maintains-35-price-target

RBC Capital analyst Luca Issi reiterates Verve Therapeutics (NASDAQ:VERV) with a Outperform and maintains $35 price target.